CoChat
Sign Up
Cited by 362

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures

Vezzani, Annamaria, Maroso, Mattia, Balosso, Silvia, Sanchez, Manuel-Alavez, Bartfai, Tamas·2011·Brain, Behavior, and Immunity
DOI 10.1016/j.bbi.2011.03.018
Open this paper in CoChat — free account

Abstract

Increasing evidence supports the involvement of immune and inflammatory processes in the etiopathogenesis of seizures. In particular, activation of innate immune mechanisms and the subsequent inflammatory responses, that are induced in the brain by infection, febrile seizures, neurotrauma, stroke are well documented conditions associated with acute symptomatic seizures and with a high risk of developing epilepsy. A decade ago, pharmacological experiments showed that elevated brain levels of the anti-inflammatory molecule IL-1 receptor antagonist reduced seizures in epilepsy models. This observation, together with the evidence of in situ induction of inflammatory mediators and their receptors in experimental and human epileptogenic brain tissue, established the proof-of-concept evidence that the activation of innate immunity and inflammation in the brain are intrinsic features of the pathologic hyperexcitable tissue. Recent breakthroughs in understanding the molecular organization of the innate immune system first in macrophages, then in the different cell types of the CNS, together with pharmacological and genetic studies in epilepsy models, showed that the activation of IL-1 receptor/Toll-like receptor (IL-1R/TLR) signaling significantly contributes to seizures. IL-1R/TLR mediated pro-excitatory actions are elicited in the brain either by mimicking bacterial or viral infections and inflammatory responses, or via the action of endogenous ligands. These ligands include proinfl…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2011.03.018

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 86

  1. Alheim, 1998, The interleukin-1 system: receptors, ligands, and ICE in the brain and their involvement in the fever response, Ann. N. Y. Acad. Sci., 840, 51, 10.1111/j.1749-6632.1998.tb09548.x · DOI
  2. Allan, 2005, Interleukin-1 and neuronal injury, Nat. Rev. Immunol., 5, 629, 10.1038/nri1664 · DOI · Paper page
  3. Auvin, 2010, Inflammation enhances epileptogenesis in the developing rat brain, Neurobiol. Dis., 40, 303, 10.1016/j.nbd.2010.06.004 · DOI
  4. Balosso, 2008, A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta, Brain, 131, 3256, 10.1093/brain/awn271 · DOI
  5. Ban, 1991, Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus, Neuroscience, 43, 21, 10.1016/0306-4522(91)90412-H · DOI
  6. Banks, 1989, Bidirectional transport of interleukin-1 alpha across the blood-brain barrier, Brain Res. Bull., 23, 433, 10.1016/0361-9230(89)90185-8 · DOI
  7. Bartfai, 2007, Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma, Ann. N. Y. Acad. Sci., 1113, 173, 10.1196/annals.1391.022 · DOI
  8. Beutler, 2000, Tlr4: central component of the sole mammalian LPS sensor, Curr. Opin. Immunol., 12, 20, 10.1016/S0952-7915(99)00046-1 · DOI
  9. Beutler, 2004, Inferences, questions and possibilities in Toll-like receptor signalling, Nature, 430, 257, 10.1038/nature02761 · DOI
  10. Bsibsi, 2002, Broad expression of Toll-like receptors in the human central nervous system, J. Neuropathol. Exp. Neurol., 61, 1013, 10.1093/jnen/61.11.1013 · DOI
  11. Carvey, 2009, The blood-brain barrier in neurodegenerative disease: a rhetorical perspective, J. Neurochem., 111, 291, 10.1111/j.1471-4159.2009.06319.x · DOI
  12. Chakravarty, 2005, Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines, J. Neurosci., 25, 1788, 10.1523/JNEUROSCI.4268-04.2005 · DOI · Paper page
  13. Choi, 2009, Cellular injury and neuroinflammation in children with chronic intractable epilepsy, J. Neuroinflamm., 6, 38, 10.1186/1742-2094-6-38 · DOI
  14. Coeshott, 1999, Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3, Proc. Natl. Acad. Sci. USA, 96, 6261, 10.1073/pnas.96.11.6261 · DOI
  15. Davis, 2006, MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics, Proc. Natl. Acad. Sci. USA, 103, 2953, 10.1073/pnas.0510802103 · DOI
  16. Davis, 2006, IL-1beta induces a MyD88-dependent and ceramide-mediated activation of Src in anterior hypothalamic neurons, J. Neurochem., 98, 1379, 10.1111/j.1471-4159.2006.03951.x · DOI
  17. De Simoni, 2000, Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus, Eur. J. NeuroSci., 12, 2623, 10.1046/j.1460-9568.2000.00140.x · DOI
  18. Diem, 2003, Interleukin-1 beta protects neurons via the interleukin-1 (IL-1) receptor-mediated Akt pathway and by IL-1 receptor-independent decrease of transmembrane currents in vivo, Mol. Cell. Neurosci., 22, 487, 10.1016/S1044-7431(02)00042-8 · DOI
  19. Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720, 10.1182/blood-2010-07-273417 · DOI · Paper page
  20. Eklind, 2006, Effect of lipopolysaccharide on global gene expression in the immature rat brain, Pediatr. Res., 60, 161, 10.1203/01.pdr.0000228323.32445.7d · DOI
  21. Eriksson, 1998, Kainic acid induced expression of interleukin-1 receptor antagonist mRNA in the rat brain, Brain Res. Mol. Brain Res., 58, 195, 10.1016/S0169-328X(98)00125-9 · DOI
  22. Fukao, 2003, PI3K and negative regulation of TLR signaling, Trends Immunol., 24, 358, 10.1016/S1471-4906(03)00139-X · DOI
  23. Galic, 2009, Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats, Neurobiol. Dis., 36, 343, 10.1016/j.nbd.2009.07.025 · DOI
  24. Gibson, 2006, Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis, J. Dent. Res., 85, 106, 10.1177/154405910608500202 · DOI
  25. Glass, 2010, Mechanisms underlying inflammation in neurodegeneration, Cell, 140, 918, 10.1016/j.cell.2010.02.016 · DOI · Paper page
  26. Gupta, 2002, Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats, Pharmacol. Biochem. Behav., 71, 245, 10.1016/S0091-3057(01)00663-3 · DOI
  27. Hanisch, 2007, Microglia: active sensor and versatile effector cells in the normal and pathologic brain, Nat. Neurosci., 10, 1387, 10.1038/nn1997 · DOI · Paper page
  28. Henshall, 2000, Alterations in bcl-2 and caspase gene family protein expression in human temporal lobe epilepsy, Neurology, 55, 250, 10.1212/WNL.55.2.250 · DOI
  29. Herman, 2002, Epilepsy after brain insult: targeting epileptogenesis, Neurology, 59, S21, 10.1212/WNL.59.9_suppl_5.S21 · DOI
  30. Huttunen, 2004, Amphoterin as an extracellular regulatior of cell motility: from discovery to disease, J. Inter. Med., 255, 351, 10.1111/j.1365-2796.2003.01301.x · DOI
  31. Iyer, 2010, Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias, Epilepsia, 51, 1763, 10.1111/j.1528-1167.2010.02547.x · DOI
  32. Kulkarni, 2009, Cyclooxygenase in epilepsy: from perception to application, Drugs Today (Barc), 45, 135, 10.1358/dot.2009.45.2.1322481 · DOI
  33. Lai, 2006, Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons, J. Neuroimmunol., 175, 97, 10.1016/j.jneuroim.2006.03.001 · DOI · Paper page
  34. Lee, 2007, Signaling pathways downstream of pattern-recognition receptors and their cross talk, Annu. Rev. Biochem., 76, 447, 10.1146/annurev.biochem.76.060605.122847 · DOI
  35. Leon, 2008, Discovery and development of Toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases, Pharm. Res., 25, 1751, 10.1007/s11095-008-9571-x · DOI
  36. Mantovani, 2001, Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines, Trends Immunol., 22, 328, 10.1016/S1471-4906(01)01941-X · DOI
  37. Maroso, M., Balosso, S., Ravizza, T., Iori, V., Wright, C.I., French, J., Vezzani, A., 2011. ICE/Caspase 1 inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. [Epub ahead of print]. · DOI
  38. Maroso, 2010, Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures, Nat. Med., 16, 413, 10.1038/nm.2127 · DOI · Paper page
  39. Matsuo, 2006, Increased IL-1beta production from dsRNA-stimulated leukocytes in febrile seizures, Pediatr. Neurol., 35, 102, 10.1016/j.pediatrneurol.2005.12.005 · DOI
  40. Mouihate, 2006, Oxyresveratrol dampens neuroimmune responses in vivo: a selective effect on TNF-alpha, Am. J. Physiol. Regul. Integr. Comp. Physiol., 291, R1215, 10.1152/ajpregu.00250.2006 · DOI
  41. Nguyen, 2002, Innate immunity: the missing link in neuroprotection and neurodegeneration?, Nat. Rev. Neurosci., 3, 216, 10.1038/nrn752 · DOI
  42. Oby, 2006, The blood-brain barrier and epilepsy, Epilepsia, 47, 1761, 10.1111/j.1528-1167.2006.00817.x · DOI
  43. Okun, 2010, Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis, Proc. Natl. Acad. Sci. USA, 107, 15625, 10.1073/pnas.1005807107 · DOI
  44. Okun, 2009, Toll-like receptors in neurodegeneration, Brain Res. Rev., 59, 278, 10.1016/j.brainresrev.2008.09.001 · DOI
  45. Pedrazzi, 2007, Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling, J. Immunol., 179, 8525, 10.4049/jimmunol.179.12.8525 · DOI
  46. Peltier, 2010, Human neuronal cells possess functional cytoplasmic and TLR-mediated innate immune pathways influenced by phosphatidylinositol-3 kinase signaling, J. Immunol., 184, 7010, 10.4049/jimmunol.0904133 · DOI
  47. Pitkanen, 2010, Therapeutic approaches to epileptogenesis--hope on the horizon, Epilepsia, 51, 2, 10.1111/j.1528-1167.2010.02602.x · DOI
  48. Ravizza, 2006, The IL-1beta system in epilepsy-associated malformations of cortical development, Neurobiol. Dis., 24, 128, 10.1016/j.nbd.2006.06.003 · DOI · Paper page
  49. Ravizza, 2008, Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy, Neurobiol. Dis., 29, 142, 10.1016/j.nbd.2007.08.012 · DOI
  50. Ravizza, 2006, Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy, Epilepsia, 47, 1160, 10.1111/j.1528-1167.2006.00590.x · DOI
  51. Ravizza, 2006, Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system, Neuroscience, 137, 301, 10.1016/j.neuroscience.2005.07.063 · DOI
  52. Riazi, 2010, Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability, Epilepsy Res., 89, 34, 10.1016/j.eplepsyres.2009.09.004 · DOI
  53. Rodgers, 2009, The cortical innate immune response increases local neuronal excitability leading to seizures, Brain, 132, 2478, 10.1093/brain/awp177 · DOI
  54. Rogawski, 2004, The neurobiology of antiepileptic drugs, Nat. Rev. Neurosci., 5, 553, 10.1038/nrn1430 · DOI
  55. Sakatani, 2008, Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo, J. Neurosci., 28, 10928, 10.1523/JNEUROSCI.3693-08.2008 · DOI
  56. Sanchez-Alavez, 2006, Ceramide mediates the rapid phase of febrile response to IL-1beta, Proc. Natl. Acad. Sci. USA, 103, 2904, 10.1073/pnas.0510960103 · DOI
  57. Schafers, 2008, Effect of cytokines on neuronal excitability, Neurosci. Lett., 437, 188, 10.1016/j.neulet.2008.03.052 · DOI
  58. Schonbeck, 1998, Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing, J. Immunol., 161, 3340, 10.4049/jimmunol.161.7.3340 · DOI · Paper page
  59. Seifert, 2006, Astrocyte dysfunction in neurological disorders: a molecular perspective, Nat. Rev. Neurosci., 7, 194, 10.1038/nrn1870 · DOI
  60. Shlosberg, 2010, Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury, Nat. Rev. Neurol., 6, 393, 10.1038/nrneurol.2010.74 · DOI · Paper page
  61. Singh, 2008, Central nervous system infections and epilepsy, Epilepsia, 49, 1, 10.1111/j.1528-1167.2008.01748.x · DOI
  62. Spulber, 2009, IL-1/IL-1ra balance in the brain revisited - evidence from transgenic mouse models, Brain Behav. Immun., 23, 573, 10.1016/j.bbi.2009.02.015 · DOI
  63. Srinivasan, 2004, Cell type-specific interleukin-1beta signaling in the CNS, J. Neurosci., 24, 6482, 10.1523/JNEUROSCI.5712-03.2004 · DOI
  64. Tabarean, 2006, Interleukin-1beta induces hyperpolarization and modulates synaptic inhibition in preoptic and anterior hypothalamic neurons, Neuroscience, 141, 1685, 10.1016/j.neuroscience.2006.05.007 · DOI
  65. Tang, 2007, Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits, Proc. Natl. Acad. Sci. USA, 104, 13798, 10.1073/pnas.0702553104 · DOI · Paper page
  66. Tsan, 2004, Endogenous ligands of Toll-like receptors, J. Leukoc. Biol., 76, 514, 10.1189/jlb.0304127 · DOI
  67. Turrin, 2004, Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy, Neurobiol. Dis., 16, 321, 10.1016/j.nbd.2004.03.010 · DOI
  68. van de Veerdonk, 2011, Inflammasome activation and IL-1β and IL-18 processing during infection, Trends Immunol., 32, 110, 10.1016/j.it.2011.01.003 · DOI
  69. Vercammen, 2008, Sensing of viral infection and activation of innate immunity by Toll-like receptor 3, Clin. Microbiol. Rev., 21, 13, 10.1128/CMR.00022-07 · DOI
  70. Vezzani, 2010, ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy, Curr. Opin. Investig. Drugs, 11, 43
  71. Vezzani, 2008, The role of cytokines in the pathophysiology of epilepsy, Brain Behav. Immun., 22, 797, 10.1016/j.bbi.2008.03.009 · DOI
  72. Vezzani, 1999, Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures, J. Neurosci., 19, 5054, 10.1523/JNEUROSCI.19-12-05054.1999 · DOI
  73. Vezzani, 2011, The role of inflammation in epilepsy, Nat. Rev. Neurol., 7, 31, 10.1038/nrneurol.2010.178 · DOI · Paper page
  74. Vezzani, 2000, Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice, Proc. Natl. Acad. Sci. USA, 97, 11534, 10.1073/pnas.190206797 · DOI
  75. Virgili, 2000, Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats, Neurosci. Lett., 281, 123, 10.1016/S0304-3940(00)00820-X · DOI
  76. Viviani, 2003, Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases, J. Neurosci., 23, 8692, 10.1523/JNEUROSCI.23-25-08692.2003 · DOI · Paper page
  77. Viviani, 2007, Cytokines and neuronal ion channels in health and disease, Int. Rev. Neurobiol., 82, 247, 10.1016/S0074-7742(07)82013-7 · DOI
  78. Wang, 2000, Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons, J. Pharmacol. Exp. Ther., 292, 497, 10.1016/S0022-3565(24)35318-2 · DOI · Paper page
  79. Wilkinson, 1993, Interleukin-1 beta has excitatory effects on neurons of the bed nucleus of the stria terminalis, Brain Res., 625, 342, 10.1016/0006-8993(93)91079-8 · DOI
  80. Wu, 2009, Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats, Neurochem. Res., 34, 1393, 10.1007/s11064-009-9920-0 · DOI
  81. Yoshimoto, 2006, Roles of IL-18 in basophils and mast cells, Allergol. Int., 55, 105, 10.2332/allergolint.55.105 · DOI
  82. Youn, 2005, Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex, J. Immunol., 175, 3339, 10.4049/jimmunol.175.5.3339 · DOI
  83. Zeise, 1997, Interleukin-1beta does not increase synaptic inhibition in hippocampal CA3 pyramidal and dentate gyrus granule cells of the rat in vitro, Brain Res., 768, 341, 10.1016/S0006-8993(97)00787-7 · DOI
  84. Zhang, 2010, Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation, Eur. J. Pharmacol., 636, 1, 10.1016/j.ejphar.2010.03.043 · DOI
  85. Zhang, 2008, Inhibition of NMDA-induced outward currents by interleukin-1beta in hippocampal neurons, Biochem. Biophys. Res. Commun., 372, 816, 10.1016/j.bbrc.2008.05.128 · DOI
  86. Zurolo, E., Iyer, A., Maroso, M., Carbonell, C., Anink, J.J., Ravizza, T., Fluiter, K., Spliet, W.G.M., van Rijen, P.C., Vezzani, A., Aronica, E., 2011. Activation of TLR, RAGE and HMGB1 signaling in malformation of cortical development. Brain [Epub ahead of print]. · DOI · Paper page

Cited by

Sorted by citations

See all 362

Metadata

Authors
Vezzani, A., Maroso, M., Balosso, S., Sanchez, M.-A., & Bartfai, T.
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2011-10
Volume
25
Issue
7
Pages
1281-1289
ISSN
0889-1591
DOI
10.1016/j.bbi.2011.03.018
Cited by
362
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review